Characteristics | Median Value | Correlation Coefficient (rho) | p |
---|---|---|---|
Serum HMGB1, pg/ml | 887 (0–1592) | ||
Age, yrs | 58 (53–63) | ||
Disease duration, yrs | 14 (6.8–22.2) | 0.32 | 0.006 |
DMARD | 66/81 (81%) | ||
Glucocorticoids at present | 17/81 (21%) | ||
Positive rheumatoid factor | 68/81 (84%) | ||
Erosive disease | 71/79 (90%) | ||
Larsen score | 1.18 (0.54–2.12) | 0.22 | 0.06 |
Disease Activity Score 28 joints | 5.3 (4.7–5.9) | 0.20 | 0.09 |
Swollen joint count | 9 (6–13) | 0.24 | 0.04 |
Tender joint count | 10 (5–15) | 0.22 | 0.07 |
C-reactive protein, mg/l | 9 (6–19) | 0.26 | 0.02 |
Orosomucoid, g/l | 1.1 (0.9–1.4) | 0.32 | 0.004 |
Health Assessment Questionnaire score | 1.0 (0.38–1.53) | 0.23 | 0.04 |
IL-6, pg/ml | 8.4 (2.1–35.0) | 0.28 | 0.01 |
Soluble IL-6 receptor, pg/ml | 749 (608–926) | 0.26 | 0.02 |
IL-1ß, pg/ml | 0.1 (0.1–0.3) | −0.03 | 0.81 |
IL-1 receptor antagonist, pg/ml | 406 (288–527) | 0.21 | 0.06 |
TNF-α, pg/ml | 3.4 (2.5–4.9) | −0.11 | 0.26 |
DMARD: disease-modifying antirheumatic drug; IL-6: interleukin 6; TNF-α: tumor necrosis factor-α.